Biocon Share Price
(BIOCON)
₹321.2▲0.11%
as on 04:01PM, 25 Feb 2025
Biocon Performance
Day's Low
Day's High
₹319.6Day's Price Range₹32952 Week's Low
52 Week's High
₹244.5552-Week Price Range₹404.7
| Returns % | |
| 1 Month Return | -13.25 % |
| 3 Month Return | -8.92 % |
| 1 Year Return | + 17.68 % |
| Market Stats | |
| Previous Close | ₹320.85 |
| Open | ₹324.05 |
| Volume | 41.05L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹38,563.27Cr |
Biocon Key Statistics
P/E Ratio
47.8
PEG Ratio
-14.4
Market Cap
₹38,563.27 Cr
P/B Ratio
2.91
EPS
10.81
Dividend Yield
0.19
Sector
Pharmaceuticals
ROE
0.97
Biocon Mutual Fund Holdings
Biocon Analyst Rating
based on 20 analysts
57.89%
Buy
15.79%
Hold
26.32%
Sell
Based on 20 analysts offering long term price targets for Biocon. An average target of ₹382.7
Source: S&P Global Market Intelligence
Biocon Share analysis
Biocon price forecast by 20 analysts
Upside of19.15%
High
₹452
Target
₹382.70
Low
₹260
Biocon target price ₹382.7, a slight upside of 19.15% compared to current price of ₹321.2. According to 20 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Biocon revenue growth forecast
Expected growth rate Q1, FY2027:40.01%
Forecast
Actual
Including amortisation and stock based compensations
Biocon EPS growth forecast
EPS estimate Q1, FY2027:47.89%
Forecast
Actual
Source: S&P Global Market Intelligence
Key events for Biocon Ltd
Biocon Shares Rise After YESINTEK Launch in U.S. - 25 Feb, 2025
Biocon's stock surged over 2% following the U.S. launch of YESINTEK™, a cost-effective biosimilar to Stelara® for treating chronic autoimmune diseases. The launch includes commercial payor coverage and a patient assistance program.Biocon Launches YESINTEK Biosimilar in US Market - 24 Feb, 2025
Biocon Biologics has launched YESINTEK (ustekinumab-kfce) in the US, a biosimilar to Stelara, approved for treating autoimmune diseases, enhancing patient access to cost-effective treatments.Biocon Shares Decline Amid Approval for YESINTEK - 22 Feb, 2025
Biocon shares fell 6.67% this week, closing at ₹322.50, influenced by market volatility. However, the European Commission granted approval for YESINTEK, a biosimilar for treating various conditions.Biocon Secures EU Approval for YESINTEK Biosimilar - 18 Feb, 2025
Biocon Biologics has received European Commission approval for YESINTEK, a biosimilar for autoimmune diseases. However, the company reported a significant decline in net profit and revenue. Additionally, Biocon announced the record date for its Rs. 570 Cr Commercial Paper maturity.Goldman Sachs Fined Over Biocon Biologics Investment - 17 Feb, 2025
Goldman Sachs was fined by the CCI for failing to notify its minority investment in Biocon Biologics, emphasizing the need for careful assessment of transaction rights and obligations.Biocon Expands Focus on Biosimilars and Generics - 11 Feb, 2025
Biocon is betting on new product launches in generics and biosimilars, supported by the Viatris acquisition, aiming for significant market presence and growth.Biocon Ltd Experiences Bullish Momentum and Recommendations - 06 Feb, 2025
Biocon Ltd shows strong bullish momentum with a 1.76% rise, marking three consecutive sessions of gains. Analysts recommend buying shares with targets set around Rs 425-429.Biocon Chairperson Calls for GST Relief on Cancer Drugs - 02 Feb, 2025
Kiran Mazumdar-Shaw, chairperson of Biocon Group, emphasizes the need for GST relief on locally manufactured cancer drugs to complement customs duty waivers, enhancing patient benefits.Biocon's Strategic Moves Amid Budget and Market Focus - 01 Feb, 2025
Biocon plans to list its biosimilars business by early 2026 and aims for significant market share in the US. HSBC remains optimistic despite Q3 misses, while Kiran Mazumdar Shaw emphasizes the need for clarity on budget allocations for innovation.Biocon Faces Profit Decline but Shares Rise - 31 Jan, 2025
Biocon's Q3 FY25 results show a drastic profit drop of 96.2% to ₹25.1 crore, yet shares rose 4%. The company plans an IPO by March 2026 and anticipates core margin improvements with new product launches.Biocon Reports Significant Decline in Q3 Earnings - 30 Jan, 2025
Biocon Ltd's Q3 FY25 results show a drastic 89.3% drop in net profit to ₹81 crore, alongside a 3.3% revenue decline. The company faces operational challenges reflected in reduced EBITDA and margin contraction.Biocon's ESG Score Rises Amid Stock Fluctuations - 27 Jan, 2025
Biocon's S&P Global ESG Score improved to 69, while the Board approved Rs 570 crore in commercial papers. Despite a 4.86% decline, the stock has risen 42.43% year-to-date, with a price target of Rs 436 anticipated in the coming months.
Insights on Biocon Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTRevenue Rich
Revenue is up for the last 2 quarters, 3.64K Cr → 3.87K Cr (in ₹), with an average increase of 5.8% per quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, -16.0 Cr → 25.1 Cr (in ₹), with an average increase of 163.8% per quarter
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 7.97% to 8.58% in Dec 2024 quarter
NO EFFECTAgainst Peers
In the last 3 years, Vimta Labs Ltd has given 193.7% return, outperforming this stock by 201.6%
- NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 60.64% of holdings in Dec 2024 quarter
- NO EFFECT
Against Peers
In the last 1 year, Vimta Labs Ltd has given 83.2% return, outperforming this stock by 65.5%
NEGATIVE IMPACTFII Holding Down
Foreign Institutions have decreased holdings from 5.93% to 5.66% in Dec 2024 quarter
- NEGATIVE IMPACT
Price Dip
In the last 7 days, BIOCON stock has moved down by -4.6%
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 18.75% to 18.12% in Dec 2024 quarter
Biocon Financials
Index Inclusions
Biocon Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 60.64% | 0.00 | |
| Foreign Institutions | 5.66% | ||
| Mutual Funds | 8.58% | 7.71 | |
| Retail Investors | 18.12% | ||
| Others | 7% | 4.30 |
Biocon Key Indicators
Biocon Valuation
Biocon in the last 5 years
Lowest (24.48x)
March 19, 2024
Today (47.80x)
February 25, 2025
Industry (50.89x)
February 25, 2025
Highest (118.86x)
September 27, 2018
Biocon Earnings and Dividends
Biocon Ltd Earnings Results
Biocon Ltd’s net profit fell -96.2% since last year same period to ₹25.10Cr in the Q3 2024-2025. On a quarterly growth basis, Biocon Ltd has generated 256.88% jump in its net profits since last 3-months.
Read More about Earnings ResultsBiocon Ltd Dividends May,2024
In the quarter ending March 2024, Biocon Ltd has declared dividend of ₹0.50 - translating a dividend yield of 0.62%.
Read More about Dividends
Biocon Technicals Summary
Bearish
Neutral
Bullish
Biocon Ltd is currently in a Bearish trading position according to technical analysis indicators.
Biocon Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹38,563.27 Cr | 1.5% | 0.58 | ₹1,297 Cr | ₹14,755 Cr | |
| HOLD | ₹1,52,017.93 Cr | 33.47% | 0.50 | ₹1,600 Cr | ₹7,845 Cr | |
| BUY | ₹1,02,579.90 Cr | 33.86% | 0.67 | ₹1,656 Cr | ₹10,727 Cr | |
| HOLD | ₹26,325.68 Cr | -2.44% | 0.50 | ₹772 Cr | ₹5,664 Cr | |
| BUY | ₹1,18,182.20 Cr | 49.32% | 0.50 | ₹4,155 Cr | ₹25,774 Cr |
About Biocon
Biocon's top products include insulin, monoclonal antibodies, enzymes, and vaccines. Its popular brands include Insugen, Insupen, and Insugen Plus. The company has a strong presence in the Indian market and is expanding its reach to other countries. Biocon has also established its presence in the US, Europe, and Japan.
Share Price: ₹321.20 per share as on 25 Feb, 2025 04:01 PM
Market Capitalisation: ₹38,563.27Cr as of today
Revenue: ₹3,773.00Cr as on December 2024 (Q4 24)
Net Profit: ₹81.10Cr as on December 2024 (Q4 24)
Listing date: 07 Apr, 2004
Chairperson Name: Kiran Mazumdar Shaw
| Organisation | Biocon |
| Headquarters | Bangalore |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
FAQs on Biocon Ltd
What is Biocon Ltd price today?
Biocon Ltd share price today stands at ₹321.2, Open: ₹324.05, Previous Close: ₹320.85, High: ₹329, Low: ₹319.6, 52 Week High: ₹404.7, 52 Week Low: ₹244.55.
How to Buy Biocon Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Biocon Ltd shares
Is Biocon Ltd listed on NSE?
Biocon Ltd is listed on NSE
Is Biocon Ltd listed on BSE?
Biocon Ltd is listed on BSE
What are today's High and Low prices of Biocon Ltd?
- Today's highest price of Biocon Ltd is ₹329.
- Today's lowest price of Biocon Ltd is ₹319.6.
What are today's traded volumes of Biocon Ltd?
Today's traded volume of Biocon Ltd(BIOCON) is 41.05L.
What is today's market capitalisation of Biocon Ltd?
Today's market capitalisation of Biocon Ltd(BIOCON) is ₹38563.27Cr.
What is the 52 Week High and Low Range of Biocon Ltd?
How much percentage Biocon Ltd is down from its 52 Week High?
Biocon Ltd (BIOCON) share price is ₹321.2. It is down -20.63% from its 52 Week High price of ₹404.7
How much percentage Biocon Ltd is up from its 52 Week low?
Biocon Ltd (BIOCON) share price is ₹321.2. It is up 31.34% from its 52 Week Low price of ₹244.55
What are the historical returns of Biocon Ltd?
What is the PE ratio of Biocon Ltd today?
PE Ratio of Biocon Ltd is 47.8
PE ratio = Biocon Ltd Market price per share / Biocon Ltd Earnings per share